Theravance Biopharma (TBPH) Misses Q1 EPS by 5c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts TBPH Hot Sheet
Join SI Premium – FREE
Theravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($0.27), $0.05 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $15.4 million versus the consensus estimate of $15.14 million.
For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stellantis N.V. (STLA) Misses Q3 EPS by 3c
- Precision Drilling (PDS) Misses Q3 EPS by 17c
- Kotak Upgrades Larsen & Toubro Ltd. (LT:IN) (LTOUF) to Buy (1)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
